M&A Deal Summary |
|
|---|---|
| Date | 2016-09-08 |
| Target | Dermasilk Brands |
| Sector | Consumer Products |
| Buyer(s) | Ember Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2010 |
| Sector | Life Science |
Ember Therapeutics, Inc. is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Consumer Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Connecticut M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2016 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-21 |
Migralex
Greenlawn, New York, United States Migralex, Inc. is a pharmaceutical company developer of medication for treating pain. |
Buy | - |
